CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period.
Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.
Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF
Presenter: Chelsky D
Affiliation: CSO, Caprion Biosciences, Inc., Montreal, Quebec, Canada
Background/Objective: Early detection markers are critical for neurodegenerative diseases since substantial, irreversible damage to the brain occurs by the time of clinical diagnosis. Markers of disease progression are also important, as established clinical assessment tools can require a year or more to detect changes. Current efforts in our laboratory include developing such markers in Alzheimer’s, Parkinson’s, and Huntington’s diseases.
Design: Candidate biomarkers were identified in the literature for each disease, and targeted metabolic response modifiers (MRM) mass spectrometry assays were assembled. In the case of Huntington’s disease, very few candidate markers were known in the literature, so a label-free liquid chromatography–tandem mass spectrometry (LC-MS/MS) disc...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research
More News: Academia | Addiction | Advertising | African Health | AIDS Vaccine | Alcoholism | ALS | Alzheimer's | Anxiety | AstraZeneca | Austria Health | Biomedical Engineering | Bipolar | Brain | Bupropion | Calcium | Canada Health | Child Abuse | Child Development | Children | Classrooms | Clinical Trials | Computers | Concussion | Cyclobenzaprine | Databases & Libraries | Dementia | Denmark Health | Depression | Disability | Education | Epilepsy | Generalized Anxiety Disorder (GAD) | Genetics | Grants | Health Insurance | HIV AIDS | Insurance | International Medicine & Public Health | Internet | Laboratory Medicine | Lamictal | Learning | Malaria | Malaria Vaccine | Mania | Men | Mexico Health | Multiple Sclerosis | Nanotechnology | Neurology | Neuroscience | Nicotine | Occupational Health | Pfizer | Psychiatry | Psychology | Rosemary | Schizophrenia | Science | Sexual Dysfunction | Sleep Disorders | Sleep Medicine | Social Anxiety Disorder | Sodium | Sodium Chloride | Sports Medicine | Statistics | Stroke | Study | Suicide | Sweden Health | Taiwan Health | Teaching | Training | Tuberculosis | Universities & Medical Training | USA Health | Vaccines | Wellbutrin | WHO | Women | Yale